AIM ImmunoTech

Develops Ampligen (rintatolimod), an experimental immunotherapy intended to activate an innate immune receptor and modify tumor microenvironments. The central program, DURIPANC, combines Ampligen with AstraZeneca's durvalumab after FOLFIRINOX for metastatic pancreatic ductal adenocarcinoma; the study has completed enrollment.

Maintains an expanded-access, cost-recovery protocol for severely debilitated ME/CFS and post-COVID fatigue, which generates essentially all reported revenue in the United States. Its other asset, Alferon N Injection, is FDA-approved for certain external genital warts but is not being manufactured or sold.

Operates as a single research-and-development segment with a small internal organization and external academic, pharmaceutical, trial-administration, access, and manufacturing partners. Development is concentrated on Ampligen and the DURIPANC data set; regulatory approvals, external financing, partner execution, and limited manufacturing capacity remain structural dependencies.